Clearmind Medicine Inc.

Contributing Author

Recent Articles by Clearmind Medicine Inc.

Jan-20	Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 CMND GlobeNewswire
Jan-14	Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 CMND GlobeNewswire
Dec-31	Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement CMND GlobeNewswire
Dec-24	Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth CMND GlobeNewswire
Dec-16	Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 CMND GlobeNewswire
Dec-12	Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment CMND GlobeNewswire
Dec-12	Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement CMND GlobeNewswire
Dec-10	Clearmind Medicine Announces 1-for-40 Reverse Share Split CMND GlobeNewswire
Dec-05	Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification CMND GlobeNewswire
Dec-02	Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder CMND GlobeNewswire
Dec-01	Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial CMND GlobeNewswire
Nov-25	Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial CMND GlobeNewswire
Nov-24	Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review CMND GlobeNewswire
Nov-20	Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site CMND GlobeNewswire
Nov-18	Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder CMND GlobeNewswire
Nov-17	Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression CMND GlobeNewswire
Nov-13	Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center CMND GlobeNewswire
Nov-12	Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment CMND GlobeNewswire
Nov-10	Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder CMND GlobeNewswire
Nov-06	Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency CMND GlobeNewswire
Nov-05	Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing CMND GlobeNewswire
Oct-31	Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy CMND GlobeNewswire
Oct-30	Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder CMND GlobeNewswire
Oct-28	Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar CMND GlobeNewswire
Oct-27	Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement CMND GlobeNewswire
Oct-21	Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder CMND GlobeNewswire
Oct-20	Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders CMND GlobeNewswire
Sep-25	Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies CMND GlobeNewswire
Sep-19	Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities CMND GlobeNewswire
Aug-07	Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar CMND GlobeNewswire
Aug-05	Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center CMND GlobeNewswire
Jul-30	Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease CMND GlobeNewswire
Jul-23	Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder CMND GlobeNewswire
Jul-15	Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled CMND GlobeNewswire
Jul-03	Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center CMND GlobeNewswire
Jun-30	Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder CMND GlobeNewswire
Jun-27	Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market CMND GlobeNewswire
Jun-25	Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment CMND GlobeNewswire
Jun-24	Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics CMND GlobeNewswire
Jun-23	Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder CMND GlobeNewswire
Jun-12	Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics CMND GlobeNewswire
Jun-05	Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment CMND GlobeNewswire
May-20	Clearmind Medicine to Host Live Webinar "Gazing Through the Crystal Ball" Featuring Leading Psychedelic Experts CMND GlobeNewswire
May-12	Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction CMND GlobeNewswire

Clearmind Medicine Inc.

Recent Articles by Clearmind Medicine Inc.

Upgrade your FINVIZ experience